Clinical Study
A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study
Table 1
Baseline Characteristics.
| | Characteristic | EZE + Statin | STAT2 | Value | | | (Between-Group) |
| | Age, years, mean ± SD | 60 ± 10 | 54 ± 13 | 0.048 | | Women, (%) | 14 (41.2) | 9 (30.0) | 0.437 | | Weight, kg, mean ± SD | | 74.8 ± 13.4 | 0.310 | | Overweight (Body Mass Index > 27 kg/m2), (%) | 9 (26.5) | 11 (36.7) | 0.380 | | Country of Ethnic Origin, (%) | | | 0.660 | | India | 14 (41.2) | 10 (33.3) | | | Pakistan | 5 (14.7) | 6 (20.0) | | | Sri Lanka | 13 (38.2) | 10 (33.3) | | | Other | 2 (5.9) | 4 (13.3) | | | Known Coronary Artery Disease, (%) | 16 (47.1) | 15 (50.0) | 0.814 | | Diabetes*, (%) | 22 (64.7) | 21 (70.0) | 0.653 | | Hypertension*, (%) | 20 (58.8) | 13 (43.3) | 0.216 | | Current smoker, (%) | 1 (2.9) | 3 (10.0) | 0.506 | | Metabolic Syndrome**, (%) | 9 (26.5) | 8 (26.7) | >0.999 | | Abdominal obesity | 21 (61.2) | 21 (70.0) | | | Elevated triglycerides | 9 (26.5) | 6 (20.0) | | | Elevated fasting blood glucose | 10 (29.4) | 10 (33.3) | | | Low HDL cholesterol | 19 (55.6) | 13 (43.3) | | | Elevated blood pressure 130/85 mmHg | 2 (5.9) | 8 (26.7) | | | History of Statin Use, (%) | | | | | Before study | | | | | Atorvastatin | 22 (64.7) | 23 (76.7) | | | Rosuvastatin | 6 (17.6) | 5 (16.7) | | | Simvastatin | 3 (8.8) | 1 (3.3) | | | Statin therapy at Baseline | | | | | Atorvastatin | 34 (100.0) | 30 (100.0) | | | 10 mg | 14 (41.2) | 13 (43.3) | | | 20 mg | 14 (41.2) | 8 (26.7) | | | 40 mg | 4 (11.8) | 7 (23.3) | |
|
|
*Treated by medication **Metabolic syndrome definition: 3 of these risk factors: abdominal obesity (waist circumference > 90 cm (men) or >80 cm (women)); elevated triglycerides 1.7 mmol/L; elevated fasting blood glucose level 6.2 mmol/L; low HDL-Cholesterol level (<1.0 mmol/L (men) and <1.3 mmol/L (women)) and elevated blood pressure > 130/85 mm Hg
|
